[1] Aarons L, Karlsson M O, Mentré F, et al. Role of modelling and simulation in Phase I drug development[J]. European Journal of Pharmaceutical Sciences, 2001, 13(2): 115-122.
[2] Sheiner L B, Steimer J L. Pharmacokinetic/pharmacodynamic modeling in drug development[J]. Annual Reviews of Pharmacology and Toxicology, 2000, 40:67-95.
[3] Karlsson M O, Jonsson E N, Wiltse C G, et al. Assumption testing in population pharmacokinetic models: illustrated with an analysis of Moxonidine data from congestive heart failure patients [J]. Journal of Pharmacokinetics and Pharmacodynamics, 1998, 26(2):207-246.
[4] Karlsson M O, Beal S L, Sheiner L B. Three new residual error models for population PK/PD analyses [J]. Journal of Pharmacokinetics and Pharmacodynamics, 1995, 23(6):651-672.
[5] Kristensen N R, Madsen H, Ingwersen S H. Using stochastic differential equations for PK/PD model development [J]. Journal of Pharmacokinetics and Pharmacodynamics, 2005, 32(1):109-141.
[6] Krishna R. Applications of pharmacokinetic principles in drug development [M]. Springer, 2004: 166-257.
[7] Kristensen N R, Madsenb H, Jørgensena S B. Parameter estimation in stochastic grey-box models[J]. Automatica, 2004, 40(2):225-237.
[8] Overgaard R V, Jonsson N, Tornøe C W, et al. Nonlinear mixed-effects models with stochastic differential equations: implementation of an estimation algorithm[J]. Journal of Pharmacokinetics and Pharmacodynamics, 2005, 32(1):85-107.
[9] Tornøe C W, Overgaard R V, Agersø H, et al. Stochastic differential equations in NONMEM: implementation, application, and comparison with ordinary differential equations[J]. Pharmaceutical Research, 2005, 22(8):1247-1258.
[10] Donnet S, Foulley J L, Samson A. Bayesian analysis of growth curves using mixed models defined by stochastic differential equations[J]. Biometrics, 2010, 66(3):733-741.
[11] Struthers C A, Mcleish D L. A particular diffusion model for incomplete longitudinal data:application to the multicenter ADIS cohort study[J]. Biostatistics, 2011, 12(3):493-505.
[12] De la Cruz-Mesía R, Marshall G. Nonlinear random effects models with continuous time autoregressive errors: a Bayesian approach[J]. Statistics in Medicine, 2005, 25(9):1471-1484.
[13] Carlin B P, Louis T A. Bayes and empirical Bayes methods for data analysis [M]. Chapman and Hall/CRC, 2000: 378-390.
[14] Carlin B P, Louis T A. Bayes and empirical Bayes methods for data analysis[J]. Statistics and Computing, 1997, 7(2):153-154.
[15] Mengersen K L, Tweedie R L. Rates of convergence of the Hastings and Metropolis algorithms[J]. Annals of Statistics, 1996, 24(1):101-121.
[16] Polli J E, Rekhi G S, Augsburger L L, et al. Methods to compare dissolution profiles and a rationale for wide dissolution specifications for metoprolol tartrate tablets[J]. Journal of Pharmaceutical Sciences, 1997, 86(6):690-700.
[17] Lánský P, Weiss M. Classification of dissolution profiles in terms of fractional dissolution rate and a novel measure of heterogeneity[J]. Journal of Pharmaceutical Sciences, 2003, 92(8):1632-1647.
[18] Lánský P, Lánskác V, Weissd M. A stochastic differential equation model for drug dissolution and its parameters[J]. Journal of Controlled Release, 2004, 100(2):267-274.